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Abstract
Alzheimer’s disease (AD) is a neurodegenerative disease, the most common cause of 
dementia in senile population. According to the World Health Organization, AD repre‐
sents around 12% of people over 65 worldwide. Due to its etiological agents, neurofibril‐
lary tangles (NFT) and amyloid plaques (AP), several attempts to explain the genesis 
and progression of AD have been proposed. Pathological variants of tau protein, are the 
main precursor for AD onset, with a molecular mechanism based on neuroinflammatory 
processes in the context of the neuroimmunomodulation theory. Microglial cells play 
preponderant roles in innate immunity and are the main source of proinflammatory fac‐
tors in the central nervous system (CNS), the links between microglia and neurons are 
the main focus on AD pathogenesis. Depending on these factors, either a neuroprotective 
or a proinflammatory effect could be triggered. In AD, a persistently active microglial 
condition generates neuronal damage and death, causing the release of pathological tau 
toward the extracellular environment. This causes the activation of microglia, promoting 
a feedback mechanism and generating a continuous cellular damage. After activation of 
microglia, generation of NF‐kB occurs, thus promoting the expression and release of pro‐
inflammatory cytokines. As a consequence, short‐lived cytotoxic factors, such as O2, NO 
and other reactive oxygen species, are released. In normal physiological conditions, tau’s 
kinases play a role in regulating normal tau functions in neurons. Glycogen synthase 
kinase 3‐beta (GSK3β)‐mediated tau phosphorylation promotes N‐methyl‐D aspartate 
receptor (NMDAr)‐mediated long‐term depression. The increase of proinflammatory 
cytokines during AD by microglia leads to an increase in kinase expression and activity 
of cyclin‐dependent kinase 5 (Cdk‐5) and GSK3‐β. On the other hand, TNF‐α and IL‐8 
increase expression and activity of Cdk5, whereas IL‐1β hyperactivates GSK3‐β, leading 
to tau hyperphosphorylation and impairing its normal function. Tau hyperphosphoryla‐
tion results in microtubule destabilization, impaired axonal transport, NMDAr‐mediated 
neurotoxicity, synaptic dysfunction and cell death. Finally, the previously summarized 
mechanisms could explain the onset and progression of AD, opening a new projection to 
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focus research on therapeutic agents that could modulate the interactions between tau 
and microglial cells. The neuroimmunomodulation mechanism has been the conceptual 
framework for the search of therapeutic approaches for AD and other neurodegenerative 
disorders.
Keywords: Alzheimer’s disease, natural compounds, molecular networks, molecular 
functions, prevalent neurological disorders, neuroimmunomodulation, inflammation
1. Introduction
1.1. Alzheimer’s disease
Alzheimer’s disease (AD) is the most common type of brain dementia in senile population (over 
60 years old) [1], which gradually affects learning and memory, displaying a prevalence and 
impact in constant expansion according to the World Health Organization (WHO). This expan‐
sive and epidemic behavior is concerning medical and public health opinion focusing efforts on 
its prevention and treatment. On its biological context, two main etiological effectors have been 
reported: (i) NFT, composed by accumulation of the hyperphosphorylated protein tau, inside 
the neuron, and assembled in oligomerical structures denominated paired helical filaments 
(PHF) [2–5] (ii) Senile plaques, composed by deposits of the amyloid‐β (Aβ) peptide of 39–42 
aminoacidic residues, generated by the proteolytic excision of the amyloid precursor protein 
(APP) by the enzymes β and γ secretases, in the extracellular space, both promoting loss of syn‐
aptic processes and neuronal death [1, 6]. Among the novel clinical studies to control progres‐
sion of this pathology, new strategies are being implemented to prevent this brain impairment 
based on dietary changes and nutritional supplements, functional foods and nutraceuticals. 
We proposed earlier that the onset of AD is a consequence of the response of microglial cells 
to “damage signals” or tau oligomers, which triggers a neuroinflammatory response, promot‐
ing the misfolding of the cytoskeleton structure [4, 7, 8]. Innovative treatments are essential to 
improve the life quality of affected subjects. Pharmaceutical industry has failed to developed 
new drugs of efficacy to control it. In this context, major attention has been given to nutraceu‐
ticals and novel bioactive compounds, such as the Andean Compound, obtained from areas 
in the north of Chilean mountains [9, 10]. We hope that this compound be effective in order to 
control the disease or serve as a coadjuvant for an effective treatment. Intensive work toward 
elucidation of the molecular mechanisms involved in the action of these compounds is being 
carried out. In addition, an advanced second phase clinical trial is actually being developed.
1.2. Neuroinflammation and neurological diseases
Neuroinflammation is defined as the response of the CNS against exogenous and/or endog‐
enous agents, which can interfere with the normal homeostatic processes in the cell. This 
inflammatory response is usually triggered from a secondary signaling cascade after a trauma 
or infection. Nevertheless, this mechanism has been characterized as one of the central axis 
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during the progression in neurodegeneration. Probably, during this secondary response, 
there will be an important loss of neurons, in contrast with the first damage [11]. The previous 
effect is also involved in every neurological disease, including developmental pathologies, 
traumatic, ischemic, metabolic, infectious, toxic ones, neoplasic and neurodegenerative disor‐
ders. Inflammation plays one of the main roles in triggering a number of different neuropa‐
thologies, such as AD, Parkinson’s or amyotrophic lateral sclerosis, among others [12]. In AD, 
a continuously active inflammatory condition could promote neural damage, consequently, 
neuronal cells death, which as a consequence induce the release of pathological forms of the 
protein tau into the extracellular environment. Since it has been reported that certain tau 
oligomers are able to activate microglial cells, they subsequently trigger a positive feedback 
mechanism, generating a constant damage to cells [7, 13, 14]. Moreover, an overexpression of 
inflammatory mediators has been reported in the vicinity of Aβ and the paired helical fila‐
ments (PHF) in AD, which, at the meantime, are associated with highly affected zones in the 
pathology [15].
Chronic metabolic diseases as hypertension, diabetes, clinical depression, dementia or trau‐
matic lesions in the brain are considered as a silent contribution to neuroinflammation [16]. In 
the same context, other risk factors causing impairment or even death in the CNS tissue are 
strokes and atherosclerosis. Moreover, during normal aging, there is a natural chronic activa‐
tion of proinflammatory signals in the same areas, contributing to an even higher vulnerabil‐
ity for neuropsychiatric disorders [17]. Finally, proinflammatory agents, IL‐6, IL‐8, C‐reactive 
protein and adipokines are correlated with clinical depression and anxiety symptoms [16, 18].
Over activation of the immune response in the CNS compromises the generation of neuro‐
tropic factors and releases of cytotoxic agents to the microglial cell [7]. Since the microglia 
have an important role in the immune system of the brain and it is widely distributed in 
every region of the CNS, especially in the hippocampal region and the substantia nigra [19], 
the effect of this positive feedback gives insights of the genesis and progression in neurode‐
generative diseases.
1.3. Microglial cells role on neuroinflammation
Microglial cells have an irregular morphology, with an enlarged nucleus and represent 
between 5 and 20% of the total glial cell population in the CNS. They are able to produce 
phagocytosis, releasing cytotoxic factors and behaving as antigen presentation cells [20]. 
These cells are derived from macrophages produced during the hematopoietic processes in 
the primitive yolk sac [21], migrating to the neural tube during development [22]. Their physi‐
ological functions are essential for the control of the normal homeostasis in the CNS, even in 
altered conditions, such as the presence of disease [15]. They are capable of sensing different 
damage signals which could represent a possible impairment for the CNS, some of them are: 
(i) microorganisms, (ii) abnormal endogenous proteins, (iii) complement factors, (iv) anti‐
bodies and (v) citoquines, chemoquines, among others. These impairment agents are able 
to interact with receptors such as toll‐like ones (TLR), inducing the cellular activation of the 
microglia [19, 23]. Under the previous conditions, microglial cells control the expression of 
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different surface markers, for example, the major histocompatibility complex II (CMH‐II) and 
pattern of molecular recognition receptors (PRRs). After these interactions, the production of 
proinflammatory cytoquines is triggered, among them: interleukin I beta (IL‐1β), interleukin 
6 (IL‐6), interleukin 8 (IL‐8), interleukin 12 (IL‐12), interferon gamma (IFN‐γ) and the tumor 
necrosis factor‐alpha (TNF‐α) [15]. At the same time, there are synthesis and release of cyto‐
toxic factors with a low biological half‐life as superoxide radicals (O
2
−), NO and other ROS 
[24, 25]. During brain development, microglial cells play the specific role in apoptotic cells 
elimination. In the cerebellum, they regulate phagocytosis of Purkinje neurons after cell death 
mediated by caspase‐3. Therefore, microglia have been implicated with synapse removal dur‐
ing development after birth [26]. Finally, the activation process for these cells will be related 
to the intensity, context and kind of stimulus generated and, depending on these factors, 
the microglia could trigger a neuroprotector or neuroinflammatory effect. Precisely, it is the 
equilibrium between neurotoxicity and neuroprotection, which will determine the microglia 
functional effect in neurological diseases or/and specific condition [15].
As we said previously, microglial cells mediate the immune response in the CNS. In order to 
accomplish this task, the microglia will turn into a functional polarized state, being able to 
carry out a specific effector program. This brain cellular type exhibits two polarized forms: 
one of them develops the classical proinflammatory response, being the most common pheno‐
type. The alternative form generates an anti‐inflammatory effect directed to heal an affected 
zone by an acute injury [27].
Additionally, microglial cells are characterized by the expression of several receptors in the 
membrane surface and also, by the release of different soluble factors. The activated cell, with 
the proinflammatory phenotype, promotes the regulation of Fc receptors as CD16, CD32, 
CD64, CD86, IL‐1b, IL‐6, IL‐12, IL‐23, TNF‐α, inducible nitric oxide synthase (iNOS) and che‐
mokines; meanwhile, the alternative anti‐inflammatory phenotype regulates positive argi‐
nase‐1 (Arg‐1), the mannose receptor (CD206), insulin growth factor‐1 (IGF‐1), the triggering 
receptor expressed in myeloid cells 2 (TREM1), chitinase 3‐like 3 (Ym‐1), among others. All 
previous proteins contribute the active microglia in order to produce additional cytokines and 
inflammatory mediators which could direct the neurons to apoptotic mechanisms in multiple 
neurodegenerative pathologies [12]. Although microorganisms and their related secreted 
proteins (LPS among them) are recognized by the Toll receptors family, neurons suffering 
apoptosis are sensed by different receptor systems, such as asialoglycoproteins, vitronectin 
and phosphatidylserine mediated ones [28].
Recent reports have demonstrated that after the microglial cells are activated, they overex‐
press several receptors and ligands belonging to the main chemokines families (CC, CXC 
and CX3C). Some of these are also expressed in astrocytes, which suggest that chemokines 
may serve as communication signals between them and microglia. It has been proposed that 
CX3CR1 and its ligand, fractaline (CX3CL1), which are expressed in neurons too, play a par‐
amount role in neuronal signaling with the microglial cells [29]. There are diverse factors 
regulating the phagocytic activity of microglial cells, one of them is the chloride intracellular 
channel (CLIC1). The pharmacological inhibition of this channel or its negative regulation of 
its expression at transcriptional level, by an interference RNA, alters the normal phagocytic 
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activity of the microglia. On the other hand, it has been reported that the ciliary neurotrophic 
factor (CNTF) promotes the phagocytosis in a way mediated by Ca2+ [30]. In conclusion, 
microglial cells can receive stimulus by environmental agents or endogenous proteins, which 
triggers an over activated state, releasing proinflammatory factors, ROS, reactive nitrogen 
species (RNS) and, evoking toxicity in the vicinity of neuronal population [31].
1.4. Astrocytes and their role in neuroinflammation
Another cellular type implicated with neuroinflammation is the astrocyte, which is the most 
widely and heterogeneously distributed glial class cell in the CNS. Their morphology can 
change depending on the development, sub‐type and localization of the CNS [32]. This kind 
of cells has been considered as the support in the brain; nowadays, it is known that they dis‐
play several functions in the CNS and that they are seriously implicated with neurodegenera‐
tive diseases. Astrocytes do not generate action potentials, although are excitable cells with 
the properties of communication with themselves or with neurons. Their activation is medi‐
ated by inner and/or external signals, sending specific messages to their neighbor cells. This 
process is called “gliotransmission” [33]. During the astrocyte/cells communication, there is a 
transitory increase in the intracellular calcium concentration. These variations are responsible 
for this cross‐talking, and they occur in two different ways: (i) as intrinsic oscillations result‐
ing after the release of intracellular calcium (spontaneous excitability) and (ii) induced by 
neurotransmitters. In the last case, neurons release ATP or glutamate [34], activating protein 
G receptors, driving to the increase of inositol trisphosphate, which will direct the calcium 
release from the endoplasmatic reticulum to the extracellular space [35]. Some other gliotrans‐
mitters are D‐serine, a co‐agonist, as glutamate, for the NMDA receptor (Panatier et al., 2006), 
growth factors and cytokines, which promote stronger and long‐term effects over synapses, 
polyunsaturated fatty acids and steroids as estradiol and progesterone and other neuroactive 
metabolites with affinity to GABA
A
 receptors [36].
As the microglia, astrocytes are reactive to endogenous and/or exogenous injuries affect‐
ing the CNS, by a process called astrogliosis. This phenomenon triggers molecular, cellular 
and functional changes in cells, as a response to damage and CNS diseases. The undergone 
changes in astrocytes will be different according to the injury severity and will be regulated 
in order to modify the astrocytic activity, gaining or losing functionality, which could have 
an effect over circundante cells [37]. There are three severity levels: (i) mild to moderate, 
(ii) severe diffuse and (iii) severe reactive with compact glial scar. The first one increases 
the glial fibrillary acidic protein (GFAP) expression in astrocytes and triggers hypertrophy 
in the cell body and their astrocytic processes. The second does the same but the astro‐
cyte processes are more pronunciated, and there is an astrocyte overlap with a proliferation 
increase. These changes are able to conduct a long‐term tissue reorganization. Finally, on the 
third case, there is formation of a glial scar preventing the axonal regeneration and cellular 
migration, but at the same time, protecting the tissue from infectious or proinflammatory 
agents [38–41]. After astrocytes activation, the transcription factor NF‐κB, which controls 
chemokines and adhesion molecules, is also overactivated, promoting the periferic lympho‐
cytes infiltration and the improvement in the inflammatory response, which could lead to 
neurodegeneration. It has been demonstrated that blocking the transcriptional function of 
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NF‐κB in astrocytes severely reduce the inflammation, which suggest that the inhibition 
of NF‐κB in astrocytes could be a potential therapy for brain pathologies, such as AD [42]. 
Astrocytes also protect the CNS by glutamate hijack which could be potentially cytotoxic 
[43], glutathione (GSH) release in order to counteract the oxidative stress [44], Aβ peptide 
degradation (Koistinaho et al., 2004), blood‐brain barrier reconstitution [38], synaptogenesis 
promotion and dynamic modulation of synaptic transmission and neural plasticity, enhanc‐
ing the metabolic trafficking [45].
Another evidence linking the astroglial activation with the development of neurodegenera‐
tive processes makes allusion to the nuclear magnetic resonance spectroscopy, because this 
technique has allowed the discovery of consistent evidence related with a significant raise of 
myoinositol (characteristic marker of astroglial cells) in neurodegenerative diseases. This has 
been observed in the brains of patients with mild cognitive impairment (MCI) and patients 
with AD, and according to some studies, this raise is correlated with the progression of this 
pathology [12].
It has been possible to associate neurodegenerative diseases of the CNS with neuroinflammatory 
events based on the appearance of high levels of proinflammatory cytoquines during disease 
progression, like in AD, Parkinson’s disease, Huntington’s disease, multiple sclerosis, amyo‐
trophic lateral sclerosis and others [13]. For all of these diseases, neuropathological and neurora‐
diological studies have been carried out, providing evidence that neuroinflammatory responses 
could appear before the loss of neuronal cells. In this issue, robust evidence has been obtained 
about the role of certain cytokines in the direct activation of the cell cascade leading to neurode‐
generation and AD. In world population terms, AD is the most common form of dementia and 
it generally affects people older than 65 years old. The anomalous tau structures, PHF and NFT, 
cause a loss of synaptic function ending in neuronal death [46]. This neurodegeneration process 
is automatically amplified when the tau aggregates are released to the extranuclear medium. 
At the meantime, in AD, an increase of the microglial activity in the first stages of the disease 
has been observed, which could be indicative of the microglia attempts to eliminate the noxious 
elements involved in AD such as the Aβ plaques. In later stages, when the microglial cells are 
chronically exposed to injuries, they could lead to a chronic neuroinflammatory response, which 
is almost always harmful to the nervous tissue. Thus, the progressive deposition of Aβ [47] and 
the liberation of pathogenic tau protein to the extracellular medium could trigger a constant 
microglia activation [13]. Also, the neuronal loss, characteristic to this disease, contributes even 
more to the generation of residues that are liberated by these degenerating neurons, which could 
keep the microglia in a long term activation condition. Thus, the activated glial cells respond 
with an overproduction of proinflammatory cytokines like TNF‐α, IL‐1β and IL‐6, which are 
considerably increased in AD. In conclusion, neuroinflammation is a fundamental stage in the 
development of this disease, because it implicates different etiological factors for AD.
1.5. Alzheimer disease and synapse
In AD, degradation can be located in several sections of the brain, such as the entorhinal cortex, 
amygdala, cerebral cortex, forebrain and hippocampus, among others [48, 49]. Furthermore, 
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there is evidence of serious changes in glutamatergic neurons present in certain sections of 
the hippocampus, as well as frontal, temporal and parietal cortexes. These areas of the brain 
are essential for the generation of new memories and for learning processes, which is a major 
function compromised in this disease [50, 51].
The glutamatergic system works by transforming electric neural impulses with chemical 
stimuli, which allows for control of glutamate neurotransmitter in the synapse process. In the 
presynaptic neuron, vesicular transporters VGLUT1 and VGLUT2 are in charge of maintain‐
ing glutamate in the vesicle [52] for its release on the synaptic cleft following a depolarization, 
where the neurotransmitter interacts with the glutamatergic receptors in the postsynaptic 
membrane [53–55]. Two families of these receptors are present in the neural membrane, the 
iGluR (ionotropic) and mGluR (metabotropic). The first group can be divided in three classes: 
NMDA, which are permeable for Ca2+ ions, the AMPA (α‐amino‐3‐hydroxy‐5‐methyl‐4‐isox‐
azolepropionic acid) and the kainite, which are permeable for Na+ and K+ ions. On the other 
hand, there are eight metabotropic glutamate receptors associated with G‐Protein, which are 
then divided in three more groups [55]. Contrary to the ionotropic receptors, which are pri‐
marily found in the postsynaptic membrane for rapid modulation of excitatory impulses, 
metabotropic receptors are found in several membrane compartments on glial and neural 
cells [56]. Functionally, it has been suggested that group 1 of these receptors mediates inhibi‐
tory effects on a presynaptic level, group 2 would be activated in the presence of the released 
glutamate and group 3 would serve as autoreceptors [56, 57].
In a synaptic context, plasticity regulation is negatively affected by the Aβ peptide. Previous 
experiments show that soluble oligomers of the peptide are capable of blocking the long‐term 
potentiation (LTP) generation in the hippocampus, establishing in electrophysiological terms 
the relation of this compound with memory and learning processes [58–61]. At a molecular 
level, previous reports support the effect of AD on components that play roles in the glutama‐
tergic synapse. Lee et al. experiments in 2004 detected a non‐regulated overexpression of the 
metabotropic receptor 2 (Group 2) in patients with Alzheimer’s disease, which through ERK 
(extracellular signal‐regulated kinases) receptors affect the abnormal hyperphosphorylation 
of tau protein observed in the disease. Through the same methods, mRNA levels of AMPA 
receptor subunits were measured, and thus, their differential expression in the hippocam‐
pus of postmortem brains with the disease was evaluated [62]. In a different point of view, 
Shao et al. in 2011 [63] utilized two transgenic mice models (5XFAD and JNPL3) to observe, 
at different periods of time, a correlation between the development of the disease and the 
decrease of PSD‐95 protein on excitatory synapses, where AD is mediated by Aβ deposition 
or hyperphosphorylated tau protein. PSD‐95 protein has a structural role within the postsyn‐
aptic density (or PSD), where it interacts with a complex of scaffolding proteins, along which 
are NMDA ionotropic receptors that participate in synaptic transmission. The postsynaptic 
density is considered an organized structure with mainly glutamatergic receptors associated 
along with other signaling proteins and cytoskeleton elements, which work together with 
scaffold proteins in the postsynaptic membrane [63, 64]. Specifically, it has also been indicated 
that PSD‐related gene products could be impaired during this pathology [65]. On that regard, 
reports also show that the expression of several genes involved in PSD, including genes of 
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glutamate receptors, varies on different stages during growth, which would imply its relation 
to synapse development [66]. Finally, since there is evidence of the role of pro inflammatory 
microglial agents in synaptic impairment, an overview of their possible molecular effects on 
synapses is paramount in the study of new treatments.
1.6. Physiological function of cytokine‐regulated tau kinases
In neurons, there are several kinases that phosphorylates tau protein under physiological 
conditions and during AD, being Cdk5, GSK3‐β, C‐Jun‐N‐terminal kinase (JNK) regulated 
by cytokines released by astrocytes and glia. Cdk5 is a proline‐directed serine threonine 
kinase, this is, phosphorylate serine and threonine residues, particularly serine 202 (Ser202) 
and threonine 205 (Thr205) residues of tau protein, also found in PHFs. Cdk5 activity is regu‐
lated by p35 and p39, which has a short mid‐life and phosphorylates Cdk5 at its T‐loop, and 
translocates to cellular membrane. This activation and translocation of Cdk5 have important 
biological roles in cortex layer formation, neurite outgrowth, migration and differentiation 
of neurons, synapse formation and cognitive processes. Cdk5 also regulates mitochondrial 
morphology and cell survival to stress [67–69]. GSK3‐β is also a serine threonine, which phos‐
phorylates tau at threonine 221 (thr221), and its kinase activity is upregulated by phosphory‐
lation of tyrosine 216 (Tyr216) and tyrosine 279 (Tyr279) residues; meanwhile, Akt‐mediated 
phosphorylation of Ser9 and Ser21 residues inactivates its activity. GSK3‐β regulates memory 
processes by induction of LTD and inhibition of LTP, being these effects reversed by GSK3‐β 
inactivation by insulin and Wnt. Also, GSK3‐β promotes assembly of actin to form filaments 
and of tubulin, leading to microtubule formation, thus regulating the reorganization of synap‐
tic architecture [70–72]. Finally, JNK phosphorylates tau at serine 396 (Ser396) and threonine 
221 (Thr221). This kinase has three isoforms that participate in brain development, immune 
modulation, induction of LTP, neurite formation and JNK3 in particular induces cell death by 
apoptosis [67].
1.7. Physiological function of cytokine‐releasing cells: microglia and astrocytes
Microglia are the principal component of innate immune response in the brain, and the first 
line of defense of central nervous system from pathogen aggressions. Microglia phagocytes 
pathogens, and releases proinflammatory cytokines, ROS and RNS to eradicate infections. 
Microglia also participate in neurogenesis by the release of brain‐derived neurotrophic fac‐
tor (BDNF), and in remodeling of brain tissue during embryonic development and in adult 
brain by inducing apoptosis mediated by release of cytokines (TNF‐α, IL‐1β), neurotrophic 
factors (NGF) and NO, and subsequently phagocytizing apoptotic neurons, thus allowing the 
maturation of surviving cells and posterior memory and learning processes. Additionally, 
microglia play a paramount role in synaptic  plasticity, regulating presynaptic and postsyn‐
aptic processes according to their fuction [73]. Astrocytes are antigen presenting cells (APC) 
of brain where their functions are scaffolding and guidance of developing neurons, formation 
of  synapses and promoting of phagocytosis of synapses by microglia, by inducing the expres‐
sion of complement system that tags synapses for their elimination by microglia. Also, regu‐
lates the diameter of brain vessels, the blood flow to neurons in relation with synaptic activity 
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and synaptic interstitial fluid homeostasis. Astrocytes also participate and regulate synaptic 
activity by releasing vesicles that uptake neurotransmitters of synaptic interspace for their 
posterior recycling and releasing neurotransmitters, as we said previously [74].
1.8. Dysfunction of astrocytes, microglia and tau kinases hyperactivation by 
proinflammatory cytokines in AD
During AD, Aβ oligomers are, on first instance, uptaken and degraded by microglia, appar‐
ently in an attempt to maintain neuronal environment homeostasis and functionality during 
early stages of disease. Aβ is able to induce the expression of complement system and microglia 
activation at two levels: activating CR1 transmembrane receptor, which initiates the activation 
cascade of complement system, associated to cytokines and ROS release. On the other hand, 
Aβ also induces its own phagocytosis by activating Fc receptor and C3 factor of complement 
system, being the last one capable of activating microglia and induce microglial‐mediated free 
radicals release. Proinflammatory molecule C5 is downstream of activation cascade and binds 
CD88 receptor, inducing the release of IL‐1Beta and IL‐6, two proinflammatory cytokines [75]. 
Also, fibrillar Aβ binds to CD14 coreceptor of Toll‐like receptor 4 (TLR4), which recruits and 
transport TLR4 to lipid rafts, followed by recruitment of coreceptor of myeloid differentiation 
factor 2 (MID‐2) which bind to CD14/TLR4 heterodimer to form a heterotrimer CD14/TLR4/
MID‐2, that is phagocytized by the cell to cytoplasm. Thus, TLR4 binds to the myeloid differ‐
entiation primary response protein 88 (MyD88) and recruits IL‐1 receptor‐associated kinase 
(IRAK4) which in turn dissociates from MyD88 and binds to and activates tumor necrosis 
factor associated receptor factor 6 (TRAF6) forming the complex 1. The later dissociates from 
TLR4 and forms complex 2 by recruiting of transforming growth factor alpha‐related kinase 
(TAK‐1) and TAK‐1 binding protein (TAB), then IRAK4 phosphorylates TAK‐1 which in 
turn phosphorylates and activates the inhibitor of kappa beta kinases complex which phos‐
phorylates kappa beta inhibitor of NF (Ikβ). This targets to degradation by proteasome, and 
releasing NF‐κB for its translocation to the nucleus where binds to its NF transcription factor 
promoter in DNA, leading to expression of coding genes of IL‐1β, IL‐6 and TNF‐α proinflam‐
matory cytokines [76, 77]. This signaling pathway is also activated by binding of Aβ to TLR‐2, 
but this receptor does not need a coreceptor for signal transduction [77].
Astrocytes, as well as microglia, uptake Aβ, since transplanted astrocytes in hippocampal 
cells of mice, carrying the Swedish mutation of amyloid precursor protein (APPSwe) together 
with a mutation of presenilin 1 (Psen), were able to internalize Aβ oligomers deposition char‐
acteristic of these mice [78]. The phagocytosis of Aβ is mediated by CD36, CD47 and RAGE 
receptors present in cellular membrane, which subsequently activates astrocytes, promotes 
their proliferation, and induces the activation of NF‐κB signaling pathway. These receptors 
have affinity for this molecular hallmark of AD and promote its degradation by astrocytic 
lysosomes [79–83]. Unlike microglia, astrocytes do not need to be activated for its Aβ clear‐
ance ability that depends on the apolipoprotein E (ApoE)‐induced formation of cell aggre‐
gates around Aβ deposits, since astrocytes of mouse lacking the ApoE gene were unable to 
aggregate around AP [84]. Another response of astrocytes to Aβ oligomers is the increase 
of expression of glutamate transporters GLT and GLAST whose physiological function is 
to prevent excitotoxicity and promote the survival of mouse [85]. Since Aβ is able to trigger 
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excitotoxicity by the hyperactivation of NMDAr, the augment of expression of astrocytic glu‐
tamate transporters in the presence of Aβ could be a mechanism to counteract this effect [86].
During AD progression, astrogliosis and microgliosis appear before the formation of NFT and 
AP [87]. The exposition of astrocytes to Aβ oligomers triggers their activation, revealed by a 
change in astrocytic morphology from stellate to a swelling morphology with more processes 
than inactive astrocytes. The previous effect induces cellular aggregation around Aβ oligo‐
mers and also triggers calcium influx into astrocytes, activating the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase. The subsequent release of ROS and activation of 
IL‐6 induce APP processing and a major Aβ production, together with the induction of Cdk5‐
p35‐mediated tau hyperphosphorylation at Ser203 and Thr205 [88, 89]. Another astrocytic 
response to Aβ oligomers is the activation of GSK3‐β which in turn activates NMDAr present 
in membrane of these cells, triggering CREB binding protein mediated (CPB) translocation 
of NF‐κB transcription factor from cytoplasm to nucleus, where it binds to its promoter and 
induces the expression of proinflammatory cytokines like IL‐1β and TNF‐α [90–92]. IL‐1β 
and IL‐6 will contribute with the processing of APP and subsequent Aβ overproduction. IL‐6 
and IL‐1 beta trigger a positive feedback that increases Aβ and proinflammatory cytokine 
overproduction [88]. IL‐1β is able to trigger chronic activation of NF‐κB signaling pathway 
by binding to type 1 IL‐1 receptor (IL‐1R1), which recruits IL‐1 receptor accessory protein 
(IL‐1RAcP)—a co‐receptor for signal transduction—forming a trimer that later recruits and 
assembles MyD88 and IRAK4. This last one phosphorylated by itself and induced to phos‐
phorylate IRAK1 and IRAK2, subsequently recruits TRAF6 which in turn bind to E2 ligase 
complex, thus promoting ubiquitination of TAK‐1 and its binding with TRAF6 and mito‐
gen‐activated protein kinase kinase kinase (MAPKKK), forming a complex which activates 
NF‐κB signaling pathway by phosphorylation of its inhibitor Ikβ, with subsequent activation 
of JNK and COX‐2 expression [93]. Furthermore, IL‐1β induces the cleavage of tau at Asp421 
in neurons by the exacerbation of caspase 3 activation, together with the hyperphosphoryla‐
tion of tau in Ser199, Thr221, Ser396 and Ser413 due to induction of GSK3‐β activation that 
reduces the production of anti‐inflammatory cytokine IL‐10, known to inhibit NF‐κB pathway 
[88, 94–96]. TNF‐α expression activates NF‐κB and c‐Jun kinase signaling pathways, inducing 
cell proliferation and migration [88]. Both IL‐1β and TNF‐α bind to its respective receptors 
IL‐1R and TNFR, respectively, and lead to MAP kinase kinases 3 and 6‐mediated activation 
of p38‐mitogen‐activated‐protein‐kinase (p38 MAPK) by dual phosphorylation of Thr and 
Tyr residues in its kinase activation loop, leading to p38 MAPK hyperphosphorylation of 
tau at residue 356 and, to a reduction of synaptophysin expression, thus affecting synaptic 
activity [97]. These two cytokines also induce phospholipase A‐mediated production of ara‐
chidonic acid (AA), together with the NF‐κB‐mediated expression of cyclooxygenase 2 gene 
(COX‐2) which dioxygenates AA to produce prostaglandins (PG’s) like PGE2, whose binding 
to its EP3 receptor leads to a reduction of adenylyl cyclase monophosphate (cAMP) activ‐
ity and, to subsequent reduction of LTP [94, 98–100]. On the other hand, IL‐18 release pro‐
motes BACE and Ps1 mediated APP processing, caspase‐1, mediated IL‐1β activation and, tau 
 hyperphosphorylation, mediated by activation of Cdk‐5/p35 [89, 101]. Finally, IL‐6 induces 
JAK/STAT and MAPK signaling pathways, triggering Cdk5/P35 deregulation and subsequent 
tau hyperphosphorylation at Ser202 and Thr205 [102].
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Microglia, as the same as astrocytes, are activated by Aβ, turning its morphology from a cell 
with a soma and processes to an ameboid active form [73], and its activation leads to the 
expression of cytokines by astrocytes in AD, thus activated astrocytes and glia act together 
in Aβ overproduction, tau cleavage and its hyperphosphorylation. Both, hyperphosphoryla‐
tion and caspase cleavage of tau are early events of AD that make this protein more prone 
to aggregate, disassembling from microtubules, impairing microtubule stabilization, axonal 
transport and vesicle release. This leads to synaptic dysfunction, axonal degeneration and 
formation of tau oligomers, PHF and NFTs and finally to cell death [103–106]. Also, it has been 
demonstrated that tau oligomers are able to activate astrocytes and glia, triggering its uptake 
by these cells [107].
It has been demonstrated that age‐related senescence of astrocytes and microglia with aging 
diminish their Aβ phagocytic capability and that the exposure to increasing concentrations of 
a neurotoxic compound reduces glial capability to protect neurons from damage. This may 
lead to progressive Aβ accumulation and subsequent inflammation in brain tissue during AD. 
This, in turn, triggers a chronic inflammatory environment mediated by astrocytes and glia, 
changing their initial neuroprotective response to neurodegeneration mediated by proinflam‐
matory cytokines which, induces AP formation and accumulation of NFTs. This effect results 
in activation of signaling pathways that activates the expression and release of proinflamma‐
tory cytokines, in a vicious circle that finally leads to synaptic dysfunction, neurodegenera‐
tion and cell death [108, 109].
1.9. Proposed new targets and therapies for AD in the neuroimmunemodulation context
On the same autoneuroimmune context, several new targets attempt to control Alzheimer’s 
disease by modulation of the inflammatory signals (Table 1), among them, some are based 
on inhibitors of acetylcholinesterase like rivastigmine to improve cholinergic synapses which 
are severely diminished in AD, and inhibitors of N‐methyl‐D‐aspartate receptor, which are 
hyperactivated in AD and exerts excitotoxicity, however these drugs only delay the progress 
of disease [110]. As mentioned above, neuroinflammation is an early event of AD, even earlier 
than NFT and Aβ plaques formation, which makes the modulation of inflammation an attrac‐
tive target for development of new drugs for treatment and prevention of AD. One alternative 
is non‐steroidal anti‐inflammatories (NSAID’s)—such as ibuprofen, paracetamol, aspirin and 
sulindac—commonly used for treatment of other illness whose symptoms are inflammation 
(e.g., infections, headache), which appear to reduce the risk of AD onset in patients who were 
in treatment for a long period [111]. One of the mechanisms of action that has been proposed to 
explain the preventive capability of AD of these drugs is the inhibition of NF‐κB signaling path‐
way by inhibiting the phosphorylation IκBα subunit of inhibitor of kappa beta kinases complex, 
thus impairing NF‐κB release for its translocation to the nucleus and so the induction of expres‐
sion of proinflammatory cytokines [46]. Another mechanism consists of inhibition of enzymatic 
activity of cyclooxygenases, preventing the production of prostaglandins [112]. NSAIDs also 
activate the peroxisome proliferator‐activated receptor gamma (PPARγ) signaling pathway 
which induces expression of anti‐inflammatory substances, and direct Aβ processing and reduc‐
tion of its release, impairing the formation of plaques. These anti‐inflammatory drugs also act 
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inhibiting microglial and astroglial activation, thus impairing NFT and AP formation mediated 
by chronic inflammation induced by these cells [113]. However, these drugs does not work in 
patients who are already suffering of AD with cognitive impairment, and thus for the effective 
use of NSAID’s, there is necessary an early diagnosis, when inflammatory process is in course 
but prior to inflammation‐induced formation of NFT and Aβ plaque deposition [108]. Another 
approach is the use of biological active molecules of polyunsaturated fatty acids as agonists of 
PPARγ transcription factor, which inhibits the expression of proinflammatory cytokines and 
turn response of immune cells to anti‐inflammatory [114]. Another challenge to overcome for 
these approaches is tissue specificity, since these compounds inhibit signaling pathways which 
are ubiquitously expressed, which means that their use as therapy for AD would be detrimental 
for immune response against pathogens aggressions. A recent study targets ionic hemichannels 
Drug/Active agent Mechanism Reference
Rivastigmine Inhibition of AchE [110]
Memantine Inhibition of NMDAr
Non‐steroidal anti‐inflammatories Inhibition of NF‐кB signaling 
pathway
[112]
Inhibition of cyclooxygenase 
enzymatic activity
Activation of PPARγ receptor
Cannabinoids Impairment of aperture of ion 
channels of astrocytes
[115]
Inhibits tau hyperphosphorylation 
and inflammation
[119]
Quercetin Reduction of levels of IL‐6 and 
TNF‐α
[120]
Apigenin Reduction of expression of COX and 
iNOS
[118]
Curcumin Reduction of the expression of 
COX‐2, iNOS
Impairment of IL‐6, NF‐κB and 
MAPK signaling pathways
Magnesium Inhibits GSK3‐β [121]
Lithium Inhibits GSK3‐β [122]
Dihydropyridines Reduce all type of tau levels [123]
Nobiletin Reduce tau hyperphosphorylation 
and oxidative stress
[124]
Brain–Up10® Reduces tau aggregation and 
increases neuritogenesis
[9]
Table 1. Drugs or active compounds for neuroimmunomodulation therapies.
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of astrocytes by using cannabinoids to impair the aperture of astrocytic hemichannels triggered 
by proinflammatory cytokines released upon Aβ stimulation, thus impairing the activation of 
astrocytes, the release of more proinflammatory cytokines and cell death [115]. Also, the use of 
stem cells has been proposed as treatment of AD, since administration of mesenchymal stem 
cells reduces plaque formation, promotes Aβ degradation and reduces levels of proinflamma‐
tory cytokines, thus reducing microglial proliferation and general neuroinflammation, and so 
did the treatment with soluble factors, which means that stem cells could release anti‐inflamma‐
tory cytokines, and more interesting, when these cells are injected intravenously, they migrate 
to brain [116]. A disadvantage of this approach is the invasiveness of this possible treatment. 
Lately, efforts have been made to find natural compounds for effective and non‐invasive treat‐
ment against AD, like quercetin, which is a flavonoid is able to reduce astrocyte activation, 
thus reducing neuroinflammation and improving learning and memory in SAMP8 accelerated 
senescence mice which were treated with an oral formulation of quercetin nanoencapsulated 
in zein nanoparticles [117]. Another flavonoid compound with AD treatment potential is api‐
genin, which can be found, between other sources, in flowers of chamomile and grapefruit. This 
compound is able to inhibit microglia‐mediated release of IL‐6 and TNF‐α, the prostaglandin 
and NO production by inhibiting COX‐2 and iNOS enzymatic activities, respectively, and also 
inhibits the NF‐κB signaling pathway [118]. However, the most promising natural compound 
for anti‐inflammatory treatment of AD is a compound called curcumin, a polyphenol isolated 
from rhizomes of curcuma which reduces the expression of COX‐2 and iNOS, impairs IL‐6, NF‐
κB and MAPK signaling pathways, reduces astroglial activation and also prevents and reverts 
tau aggregation in vitro, which could mean that this compound could be used in AD patients 
with cognitive impairment, if it demonstrates that also have these effects in animal models and 
human, so more studies have to be made, not only for this compound but also to find or develop 
new natural or synthetic anti‐inflammatory and anti‐aggregant compounds to treat AD [118].
2. Conclusion
Alzheimer’s disease cases are growing faster every year, not even in senile population, yet 
also with early onset cases. We have studied different issues related with the beginning and 
progression of neurodegenerative pathologies. Since in a biological context, the neuroimmu‐
neinflammatory response theory could be the new focus for possible treatments, the research 
efforts to follow‐up should be focused in the control of neuroinflammatory processes.
Microglia seem to be the main brain cells in the pathological pathway of damage signals in 
the neuronal population of neurodegenerative diseases. The positive feedback cycle, between 
microglia and neurons, is started by tau oligomers released in the extracellular space after 
neuron degeneration, triggering the microglia activation (Figure 1). Different clinical trials on 
pharmacological agents attempted to stop the progress of AD or revert its consequences, but 
only a few ones, are promising. On the other hand, natural compounds have received special 
attention, because of their benefits in neuritogenesis or possible applications to control the 
progression of the inflammatory process in AD. Such is the case of “Andean Compound,” 
which we present as an alternative treatment for this pathology (Figure 1).
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We encourage researchers to set their aim in new neuroprotective and anti‐neuroinflammatory 
drugs or nutraceuticals, projecting the answers for neurodegenerative diseases on the basis of 
the neuroimmunemodulation theory, as the most valuable and useful tools for AD treatment.
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Figure 1. Model of neuroinflammation and neurodegeneration cycle modulated by the “Andean Compound.” Non‐
activated microglial cells are susceptible to different damage signals as aggregated forms of the tau protein, leading 
to its activation. After activation, several pro‐inflammatory agents are release into the extracellular media, being 
able to promote neuronal damage and degeneration. While neurons are degraded, different tau forms are released, 
causing a positive feedback in this neurodegenerative pro‐inflammatory cycle, triggering the onset and progression of 
pathologies such as AD. The Andean Compound displays and anti‐aggregation effect on tau oligomers, diminishing 
damage signals and, at the same time, it promotes neuritogenesis processes, featuring itself as an excellent target for 
the treatment of AD.
Mechanisms of Neuroinflammation90
References
[1] Bettens K, Sleegers K, Van Broeckhoven C. Current status on Alzheimer disease molec‐
ular genetics: From past, to present, to future. Human Molecular Genetics. 15 Apr 
2010;19(R1):R4‐R11
[2] Maccioni RB. Introductory remarks. Molecular, biological and clinical aspects of 
Alzheimer’s disease. Archives of Medical Research. Nov 2012;43(8):593‐594
[3] Maccioni RB, Munoz JP, Barbeito L. The molecular bases of Alzheimer’s disease and other 
neurodegenerative disorders. Archives of Medical Research. Sep–Oct 2001;32(5):367‐381
[4] Farias G, Cornejo A, Jimenez J, Guzman L, Maccioni RB. Mechanisms of tau self‐aggre‐
gation and neurotoxicity. Current Alzheimer Research. Sep 2011;8(6):608‐614
[5] Guzman‐Martinez L, Farias GA, Maccioni RB. Tau Oligomers as potential targets for 
Alzheimer’s diagnosis and novel drugs. Frontiers in Neurology 2013;4:167
[6] Lambert JC, Schraen‐Maschke S, Richard F, Fievet N, Rouaud O, Berr C, et al. Association 
of plasma amyloid beta with risk of dementia: The prospective three‐City study. 
Neurology. Sep 15 2009;73(11):847‐853
[7] Maccioni RB, Rojo LE, Fernandez JA, Kuljis RO. The role of neuroimmunomodulation in 
Alzheimer’s disease. Annals of the New York Academy of Sciences. Feb 2009;1153:240‐246
[8] Fernandez JA, Rojo L, Kuljis RO, Maccioni RB. The damage signals hypothesis of 
Alzheimer’s disease pathogenesis. Journal of Alzheimer’s Disease. Jul 2008;14(3):329‐333
[9] Carrasco‐Gallardo C, Farias GA, Fuentes P, Crespo F, Maccioni RB. Can nutraceuticals 
prevent Alzheimer’s disease? Potential therapeutic role of a formulation containing shi‐
lajit and complex B vitamins. Archives of Medical Research. Nov 2012;43(8):699‐704
[10] Carrasco‐Gallardo C, Guzman L, Maccioni RB. Shilajit: A natural phytocomplex 
with potential procognitive activity. International Journal of Alzheimer’s Disease. 
2012;2012:674142
[11] Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and 
Alzheimer’s disease. Neurobiology of Aging. May–Jun 2000;21(3):383‐421
[12] Morales I, Farias GA, Cortes N, Maccioni RB. Neuroinflammation and Neurodegeneration. 
Update on Dementia. Rijeka: InTech; 2017. p. Ch. 0
[13] Morales I, Jimenez JM, Mancilla M, Maccioni RB. Tau oligomers and fibrils induce acti‐
vation of microglial cells. Journal of Alzheimer’s Disease. 1 Jan 2013;37(4):849‐856
[14] Morales I, Guzman‐Martinez L, Cerda‐Troncoso C, Farias GA, Maccioni RB. Neuroin‐
flammation in the pathogenesis of Alzheimer’s disease. A rational framework for the 
search of novel therapeutic approaches. Frontier Cell Neuroscience. 2014;8:112
[15] Morales I, Farias G, Maccioni RB. Neuroimmunomodulation in the pathogenesis of 
Alzheimer’s disease. Neuroimmunomodulation 2010;17(3):202‐204
Neuroimmune Dynamics in Alzheimer’s Disease Progression
http://dx.doi.org/10.5772/intechopen.68941
91
[16] Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative dis‐
eases (Review). Molecular Medicine Reports. Apr 2016;13(4):3391‐3396
[17] Capuron L, Su S, Miller AH, Bremner JD, Goldberg J, Vogt GJ, et al. Depressive symptoms 
and metabolic syndrome: Is inflammation the underlying link? Biological Psychiatry. 15 
Nov 2008;64(10):896‐900
[18] Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic dis‐
ease. Nature Reviews Immunology. Feb 2011;11(2):85‐97
[19] Venneti S, Wiley CA, Kofler J. Imaging microglial activation during neuroinflammation 
and Alzheimer’s disease. Journal of NeuroImmune Pharmacology. Jun 2009;4(2):227‐243
[20] Perry VH. A revised view of the central nervous system microenvironment and major 
histocompatibility complex class II antigen presentation. Journal of Neuroimmunology. 
1 Oct 1998;90(2):113‐121
[21] Alliot F, Godin I, Pessac B. Microglia derive from progenitors, originating from the 
yolk sac, and which proliferate in the brain. Developmental Brain Research 18 Nov 
1999;117(2):145‐152
[22] Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia. 
Frontiers in Cellular Neuroscience. 2013;7:45
[23] Streit WJ, Miller KR, Lopes KO, Njie E. Microglial degeneration in the aging brain—bad 
news for neurons? Frontiers in Bioscience. 2008;13:3423‐3438
[24] Meda L, Baron P, Scarlato G. Glial activation in Alzheimer’s disease: The role of Abeta 
and its associated proteins. Neurobiology of Aging. Nov‐Dec 2001;22(6):885‐893
[25] Colton C, Wilcock DM. Assessing activation states in microglia. CNS & Neurological 
Disorders—Drug Targets. Apr 2010;9(2):174‐191
[26] Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. 
Physiological Reviews. Apr 2011;91(2):461‐553
[27] Jha MK, Lee WH, Suk K. Functional polarization of neuroglia: Implications in neuroin‐
flammation and neurological disorders. Biochemical Pharmacology. 01 Mar 2016;103:1‐16
[28] Witting A, Muller P, Herrmann A, Kettenmann H, Nolte C. Phagocytic clearance of 
apoptotic neurons by Microglia/Brain macrophages in vitro: Involvement of lectin‐, 
integrin‐, and phosphatidylserine‐mediated recognition. Journal of Neurochemistry. 
Sep 2000;75(3):1060‐1070
[29] Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, Lokensgard JR, et al. Role of microglia 
in central nervous system infections. Clinical Microbiology Reviews. Oct 2004;17(4):942‐
964, table of contents
[30] Lee TI, Yang CS, Fang KM, Tzeng SF. Role of ciliary neurotrophic factor in microglial 
phagocytosis. Neurochemical Research. Jan 2009;34(1):109‐117
Mechanisms of Neuroinflammation92
[31] Innamorato NG, Lastres‐Becker I, Cuadrado A. Role of microglial redox balance in mod‐
ulation of neuroinflammation. Current Opinion in Neurology. Jun 2009;22(3):308‐314
[32] Steardo L, Jr., Bronzuoli MR, Iacomino A, Esposito G, Steardo L, Scuderi C. Does neuro‐
inflammation turn on the flame in Alzheimer’s disease? Focus on astrocytes. Frontiers in 
Neuroscience. 2015;9:259
[33] Volterra A, Meldolesi J. Astrocytes, from brain glue to communication elements: the 
revolution continues. Nature Reviews Neuroscience. Aug 2005;6(8):626‐640
[34] Paukert M, Bergles DE. Synaptic communication between neurons and NG2+ cells. 
Current Opinion in Neurobiology. Oct 2006;16(5):515‐521
[35] Agulhon C, Petravicz J, McMullen AB, Sweger EJ, Minton SK, Taves SR, et al. What is the 
role of astrocyte calcium in neurophysiology? Neuron. 25 Sep 2008;59(6):932‐946
[36] Garcia‐Segura LM, Melcangi RC. Steroids and glial cell function. Glia. Nov 01 2006;54(6): 
485‐498
[37] Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. 
Trends in Neurosciences. Dec 2009;32(12):638‐647
[38] Bush TG, Puvanachandra N, Horner CH, Polito A, Ostenfeld T, Svendsen CN, et al. 
Leukocyte infiltration, neuronal degeneration, and neurite outgrowth after ablation of 
scar‐forming, reactive astrocytes in adult transgenic mice. Neuron Jun 1999;23(2):297‐308
[39] Faulkner JR, Herrmann JE, Woo MJ, Tansey KE, Doan NB, Sofroniew MV. Reactive 
astrocytes protect tissue and preserve function after spinal cord injury. Journal of 
Neuroscience. 03 Mar 2004;24(9):2143‐2155
[40] Silver J, Miller JH. Regeneration beyond the glial scar. Nature Reviews Neuroscience. 
Feb 2004;5(2):146‐156
[41] Voskuhl RR, Peterson RS, Song B, Ao Y, Morales LB, Tiwari‐Woodruff S, et al. Reactive 
astrocytes form scar‐like perivascular barriers to leukocytes during adaptive immune 
inflammation of the CNS. Journal of Neuroscience. 16 Sep 2009;29(37):11511‐11522
[42] Medeiros R, LaFerla FM. Astrocytes: Conductors of the Alzheimer disease neuroinflam‐
matory symphony. Experimental Neurology. Jan 2013;239:133‐138
[43] Rothstein JD, Dykes‐Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, et al. Knockout 
of glutamate transporters reveals a major role for astroglial transport in excitotoxicity 
and clearance of glutamate. Neuron. Mar 1996;16(3):675‐686
[44] Shih AY, Johnson DA, Wong G, Kraft AD, Jiang L, Erb H, et al. Coordinate regulation of 
glutathione biosynthesis and release by Nrf2‐expressing glia potently protects neurons 
from oxidative stress. Journal of Neuroscience. 15 Apr 2003;23(8):3394‐3406
[45] Perea G, Navarrete M, Araque A. Tripartite synapses: astrocytes process and control 
synaptic information. Trends in Neurosciences. Aug 2009;32(8):421‐431
Neuroimmune Dynamics in Alzheimer’s Disease Progression
http://dx.doi.org/10.5772/intechopen.68941
93
[46] Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, et al. Tangle 
and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s dis‐
ease. Neurology. 13 May 2003;60(9):1495‐1500
[47] Krause DL, Muller N. Neuroinflammation, microglia and implications for anti‐inflam‐
matory treatment in Alzheimer’s disease. International Journal of Alzheimer’s Disease. 
14 Jun 2010;2010
[48] DeKosky ST, Scheff SW, Styren SD. Structural correlates of cognition in dementia: 
Quantification and assessment of synapse change. Neurodegeneration. Dec 1996;5(4): 
417‐421
[49] Selkoe DJ, Schenk D. Alzheimer’s disease: Molecular understanding predicts amyloid‐
based therapeutics. Annual Review of Pharmacology and Toxicology. 2003;43:545‐584
[50] Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer’s disease. 
Journal of Neural Transmission. Supplementa. 1998;53:127‐140
[51] Francis PT. Glutamatergic systems in Alzheimer’s disease. International Journal of 
Geriatric Psychiatry. Sep 2003;18(Suppl 1):S15–S21
[52] Fremeau RT, Jr, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, et al. The 
expression of vesicular glutamate transporters defines two classes of excitatory synapse. 
Neuron. 02 Aug 2001;31(2):247‐260
[53] Ozawa S, Kamiya H, Tsuzuki K. Glutamate receptors in the mammalian central nervous 
system. Progress in Neurobiology. Apr 1998;54(5):581‐618
[54] Danbolt NC. Glutamate uptake. Progress in Neurobiology. Sep 2001;65(1):1‐105
[55] Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and phar‐
macology. Psychopharmacology (Berl). Apr 2005;179(1):4‐29
[56] Ferraguti F, Shigemoto R. Metabotropic glutamate receptors. Cell and Tissue Research. 
Nov 2006;326(2):483‐504
[57] Vogt KE, Nicoll RA. Glutamate and gamma‐aminobutyric acid mediate a heterosynap‐
tic depression at mossy fiber synapses in the hippocampus. PNAS, Proceedings of the 
National Academy of Sciences. 02 Feb 1999;96(3):1118‐1122
[58] Shankar GM, Li S, Mehta TH, Garcia‐Munoz A, Shepardson NE, Smith I, et al. Amyloid‐
beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity 
and memory. Nature Medicine. Aug 2008;14(8):837‐842
[59] Klyubin I, Wang Q, Reed MN, Irving EA, Upton N, Hofmeister J, et al. Protection against 
Abeta‐mediated rapid disruption of synaptic plasticity and memory by memantine. 
Neurobiology of Aging. Apr 2009;32(4):614‐623
[60] Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. Soluble oligomers of 
amyloid Beta protein facilitate hippocampal long‐term depression by disrupting neuro‐
nal glutamate uptake. Neuron. 25 Jun 2009;62(6):788‐801
Mechanisms of Neuroinflammation94
[61] Palop JJ, Mucke L. Amyloid‐beta‐induced neuronal dysfunction in Alzheimer’s dis‐
ease: from synapses toward neural networks. Nature Reviews Neuroscience. Jul 
2010;13(7):812‐818
[62] Pellegrini‐Giampietro DE, Bennett MV, Zukin RS. AMPA/kainate receptor gene expres‐
sion in normal and Alzheimer’s disease hippocampus. Neuroscience. Jul 1994;61(1):41‐49
[63] Shao CY, Mirra SS, Sait HB, Sacktor TC, Sigurdsson EM. Postsynaptic degenera‐
tion as revealed by PSD‐95 reduction occurs after advanced Abeta and tau pathol‐
ogy in transgenic mouse models of Alzheimer’s disease. Acta Neuropathologica. Sep 
2011;122(3):285‐292
[64] Revett TJ, Baker GB, Jhamandas J, Kar S. Glutamate system, amyloid ss peptides and 
tau protein: Functional interrelationships and relevance to Alzheimer disease pathology. 
Journal of Psychiatry & Neuroscience. Jan 2012;38(1):6‐23
[65] Sheng M, Hoogenraad CC. The postsynaptic architecture of excitatory synapses: a more 
quantitative view. Annual Review of Biochemistry 2007;76:823‐847
[66] Petralia RS, Sans N, Wang YX, Wenthold RJ. Ontogeny of postsynaptic density proteins 
at glutamatergic synapses. Molecular and Cellular Neuroscience. Jul 2005;29(3):436‐452
[67] Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, et al. Tau 
protein kinases: involvement in Alzheimer’s disease. Ageing Research Reviews. Jan 
2013;12(1):289‐309
[68] Liu SL, Wang C, Jiang T, Tan L, Xing A, Yu JT. The Role of Cdk5 in Alzheimer’s Disease. 
Molecular Neurobiology. Sep 2016;53(7):4328‐4342
[69] Jin X, Sasamoto K, Nagai J, Yamazaki Y, Saito K, Goshima Y, et al. Phosphorylation of 
CRMP2 by Cdk5 Regulates Dendritic Spine Development of Cortical Neuron in the 
Mouse Hippocampus. Neural Plasticity. 2016;2016:6790743
[70] Hanger DP, Noble W. Functional implications of glycogen synthase kinase‐3‐mediated 
tau phosphorylation. International Journal of Alzheimer’s Disease. 2011;2011:352805
[71] Meunier CN, Cancela JM, Fossier P. Lack of GSK3beta activation and modulation of 
synaptic plasticity by dopamine in 5‐HT1A‐receptor KO mice. Neuropharmacology. Feb 
2017;113(Pt A):124‐136
[72] Maixner DW, Weng HR. The Role of Glycogen Synthase Kinase 3 Beta in 
Neuroinflammation and Pain. Journal of Pharmacy and Pharmacology (Los Angel). 
2013;1(1):001
[73] Wake H, Moorhouse AJ, Nabekura J. Functions of microglia in the central nervous sys‐
tem‐‐beyond the immune response. Neuron Glia Biology. Feb 2011;7(1):47‐53
[74] Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathologica. 
Jan 2010;119(1):7‐35
Neuroimmune Dynamics in Alzheimer’s Disease Progression
http://dx.doi.org/10.5772/intechopen.68941
95
[75] Doens D, Fernandez PL. Microglia receptors and their implications in the response to 
amyloid beta for Alzheimer’s disease pathogenesis. Journal of Neuroinflammation. 13 
Mar 2014;11:48
[76] Rahimifard M, Maqbool F, Moeini‐Nodeh S, Niaz K, Abdollahi M, Braidy N, et al. 
Targeting the TLR4 signaling pathway by polyphenols: A novel therapeutic strategy for 
neuroinflammation. Ageing Research Reviews. 21 Feb 2017;36:11‐19
[77] Landreth GE, Reed‐Geaghan EG. Toll‐like receptors in Alzheimer’s disease. In: Kielian 
T, editor. Toll‐like Receptors: Roles in Infection and Neuropathology. Berlin, Heidelberg: 
Springer Berlin Heidelberg; 2009. pp. 137‐153
[78] Pihlaja R, Koistinaho J, Malm T, Sikkila H, Vainio S, Koistinaho M. Transplanted astro‐
cytes internalize deposited beta‐amyloid peptides in a transgenic mouse model of 
Alzheimer’s disease. Glia. 15 Jan 2008;56(2):154‐163
[79] Baker RG, Hayden MS, Ghosh S. NF‐kappaB, inflammation, and metabolic disease. Cell 
Metabolism. 05 Jan 2011;13(1):11‐22
[80] Yi B, Luye Q, Eunhee K, Sangram B, Hengchang G, Maria F, et al. CD36 is involved 
in astrocyte activation and astroglial scar formation. Journal of Cerebral Blood Flow & 
Metabolism. 2012;32(8):1567‐1577
[81] Jones RS, Minogue AM, Connor TJ, Lynch MA. Amyloid‐beta‐induced astrocytic phago‐
cytosis is mediated by CD36, CD47 and RAGE. Journal of NeuroImmune Pharmacology. 
Mar 2013;8(1):301‐311
[82] Kim J, Waldvogel HJ, Faull RL, Curtis MA, Nicholson LF. The RAGE receptor and its 
ligands are highly expressed in astrocytes in a grade‐dependant manner in the stria‐
tum and subependymal layer in Huntington’s disease. Journal of Neurochemistry. Sep 
2015;134(5):927‐942
[83] Sick E, Boukhari A, Deramaudt T, Ronde P, Bucher B, Andre P, et al. Activation of CD47 
receptors causes proliferation of human astrocytoma but not normal astrocytes via an 
Akt‐dependent pathway. Glia. Feb 2011;59(2):308‐319
[84] Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, et al. Apolipoprotein E 
promotes astrocyte colocalization and degradation of deposited amyloid‐beta peptides. 
Nature Medicine. Jul 2004;10(7):719‐726
[85] Petr GT, Sun Y, Frederick NM, Zhou Y, Dhamne SC, Hameed MQ, et al. Conditional dele‐
tion of the glutamate transporter GLT‐1 reveals that astrocytic GLT‐1 protects against 
fatal epilepsy while neuronal GLT‐1 contributes significantly to glutamate uptake into 
synaptosomes. Journal of Neuroscience. 01 Apr 2015;35(13):5187‐5201
[86] Alberdi E, Sanchez‐Gomez MV, Cavaliere F, Perez‐Samartin A, Zugaza JL, Trullas R, 
et al. Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through 
activation of ionotropic glutamate receptors. Cell Calcium. Mar 2010;47(3):264‐272
[87] Schwab C, Klegeris A, McGeer PL. Inflammation in transgenic mouse models of neuro‐
degenerative disorders. Biochimica et Biophysica Acta. Oct 2010;1802(10):889‐902
Mechanisms of Neuroinflammation96
[88] Narayan P, Holmstrom KM, Kim DH, Whitcomb DJ, Wilson MR, St George‐Hyslop P, 
et al. Rare individual amyloid‐beta oligomers act on astrocytes to initiate neuronal dam‐
age. Biochemistry. 22 Apr 2014 ;53(15):2442‐2253
[89] Wang WY, Tan MS, Yu JT, Tan L. Role of pro‐inflammatory cytokines released from 
microglia in Alzheimer’s disease. Annals of Translational Medicine. Jun 2015;3(10):136
[90] Becher B, Spath S, Goverman J. Cytokine networks in neuroinflammation. Nature 
Reviews Immunology. Jan 2017;17(1):49‐59
[91] Kawamoto EM, Lepsch LB, Boaventura MF, Munhoz CD, Lima LS, Yshii LM, et al. 
Amyloid beta‐peptide activates nuclear factor‐kappaB through an N‐methyl‐D‐aspar‐
tate signaling pathway in cultured cerebellar cells. Journal of Neuroscience Research. 
Mar 2008;86(4):845‐860
[92] Shih RH, Wang CY, Yang CM. NF‐kappaB signaling pathways in neurological inflam‐
mation: A mini review. Frontiers in Molecular Neuroscience. 2015;8:77
[93] Weber A, Wasiliew P, Kracht M. Interleukin‐1 (IL‐1) pathway. Science Signaling. 19 Jan 
2010;3(105):cm1
[94] Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W. Astrocytes are important 
mediators of Abeta‐induced neurotoxicity and tau phosphorylation in primary culture. 
Cell Death & Disease. 02 Jun 2011;2:e167
[95] Llorens‐Martin M, Jurado J, Hernandez F, Avila J. GSK‐3beta, a pivotal kinase in 
Alzheimer disease. Frontiers in Molecular Neuroscience. 2014;7:46
[96] Grunnet LG, Aikin R, Tonnesen MF, Paraskevas S, Blaabjerg L, Storling J, et al. Proin‐
flammatory cytokines activate the intrinsic apoptotic pathway in beta‐cells. Diabetes. 
Aug 2009;58(8):1807‐1815
[97] Correa SA, Eales KL. The role of p38 MAPK and its substrates in neuronal plasticity and 
neurodegenerative disease. Journal of Signal Transduction. 2012;2012:649079
[98] Kuwata H, Nakatani Y, Murakami M, Kudo I. Cytosolic phospholipase A2 is required 
for cytokine‐induced expression of type IIA secretory phospholipase A2 that mediates 
optimal cyclooxygenase‐2‐dependent delayed prostaglandin E2 generation in rat 3Y1 
fibroblasts. The Journal of Biological Chemistry. 16 Jan 1998;273(3):1733‐1740
[99] Aid S, Bosetti F. Targeting cyclooxygenases‐1 and ‐2 in neuroinflammation: Therapeutic 
implications. Biochimie. Jan 2011;93(1):46‐51
[100] Maingret V, Barthet G, Deforges S, Jiang N, Mulle C, Amedee T. PGE2‐EP3 signaling 
pathway impairs hippocampal presynaptic long‐term plasticity in a mouse model of 
Alzheimer’s disease. Neurobiology of Aging. Feb 2017;50:13‐24
[101] Ojala JO, Sutinen EM, Salminen A, Pirttila T. Interleukin‐18 increases expression of 
kinases involved in tau phosphorylation in SH‐SY5Y neuroblastoma cells. Journal of 
Neuroimmunology. 15 Dec 2008;205(1‐2):86‐93
Neuroimmune Dynamics in Alzheimer’s Disease Progression
http://dx.doi.org/10.5772/intechopen.68941
97
[102] Quintanilla RA, Orellana DI, Gonzalez‐Billault C, Maccioni RB. Interleukin‐6 induces 
Alzheimer‐type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. 
Experimental Cell Research. 15 Apr 2004;295(1):245‐257
[103] Ding H, Matthews TA, Johnson GV. Site‐specific phosphorylation and caspase cleavage 
differentially impact tau‐microtubule interactions and tau aggregation. The Journal of 
Biological Chemistry. 14 Jul 2006;281(28):19107‐19114
[104] Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause local‐
ized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphory‐
lation, and destruction of microtubules and spines. Journal of Neuroscience. 08 Sep 
2010;30(36):11938‐11950
[105] Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss 
and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 
1 Feb 2007;53(3):337‐351
[106] Cho YE, Lee MH, Song BJ. Neuronal cell death and degeneration through increased 
nitroxidative stress and tau phosphorylation in HIV‐1 transgenic rats. PLoS One 
2017;12(1):e0169945
[107] Nilson AN, English KC, Gerson JE, Barton Whittle T, Nicolas Crain C, Xue J, et al. Tau 
oligomers associate with inflammation in the brain and retina of tauopathy mice and in 
neurodegenerative diseases. Journal of Alzheimer’s Disease. 2017;55(3):1083‐1099
[108] Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, et al. Extended 
results of the Alzheimer’s disease anti‐inflammatory prevention trial. Alzheimer’s & 
Dementia. Jul 2011;7(4):402‐411
[109] Efremova L, Chovancova P, Adam M, Gutbier S, Schildknecht S, Leist M. Switching from 
astrocytic neuroprotection to neurodegeneration by cytokine stimulation. Archives of 
Toxicology. Jan 2017;91(1):231‐246
[110] Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, et al. Efficacy and safety of done‐
pezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s 
disease: A systematic review and meta‐analysis. Journal of Alzheimer’s Disease. 
2014;41(2):615‐631
[111] Gupta SC, Sundaram C, Reuter S, Aggarwal BB. Inhibiting NF‐kappaB activation by 
small molecules as a therapeutic strategy. Biochimica et Biophysica Acta. Oct‐Dec 
2010;1799(10‐12):775‐787
[112] Ajmone‐Cat MA, Bernardo A, Greco A, Minghetti L. Non‐steroidal anti‐inflammatory 
drugs and brain inflammation: Effects on microglial functions. Pharmaceuticals (Basel). 
14 Jun 2010;3(6):1949‐1965
[113] Imbimbo BP, Solfrizzi V, Panza F. Are NSAIDs useful to treat Alzheimer’s disease or 
mild cognitive impairment?. Frontiers in Aging Neuroscience. 2010;2
[114] Martin H. Role of PPAR‐gamma in inflammation. Prospects for therapeutic interven‐
tion by food components. Mutation Research. 07 Aug 2010;690(1‐2):57‐63
Mechanisms of Neuroinflammation98
[115] Gajardo‐Gomez R, Labra VC, Maturana CJ, Shoji KF, Santibanez CA, Saez JC, et al. 
Cannabinoids prevent the amyloid beta‐induced activation of astroglial hemichannels: 
A neuroprotective mechanism. Glia. Jan 2017;65(1):122‐137
[116] Harach T, Jammes F, Muller C, Duthilleul N, Cheatham V, Zufferey V, et al. 
Administrations of human adult ischemia‐tolerant mesenchymal stem cells and factors 
reduce amyloid beta pathology in a mouse model of Alzheimer’s disease. Neurobiology 
of Aging. Mar 2017;51:83‐96
[117] Moreno LC, Puerta E, Suarez‐Santiago JE, Santos‐Magalhaes NS, Ramirez MJ, Irache JM. 
Effect of the oral administration of nanoencapsulated quercetin on a mouse model of 
Alzheimer’s disease. International Journal of Pharmaceutics. 30 Jan 2017;517(1‐2):50‐57
[118] Venigalla M, Gyengesi E, Munch G. Curcumin and apigenin ‐ novel and promis‐
ing therapeutics against chronic neuroinflammation in Alzheimer’s disease. Neural 
Regeneration Research. Aug 2015;10(8):1181‐1185
[119] Bedse G, Romano A, Lavecchia AM, Cassano T, Gaetani S. The role of endocannabinoid 
signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease. 
Journal of Alzheimer’s Disease. 2015;43(4):1115‐1136
[120] Rinwa P, Kumar A. Quercetin suppress microglial neuroinflammatory response and 
induce antidepressent‐like effect in olfactory bulbectomized rats. Neuroscience 2013; 
255:86‐98
[121] Xu ZP, Li L, Bao J, Wang ZH, Zeng J, Liu EJ, et al. Magnesium protects cognitive func‐
tions and synaptic plasticity in streptozotocin‐induced sporadic Alzheimer’s model. 
PLoS One 2014;9(9):e108645
[122] Klein PS, Melton DA. A molecular mechanism for the effect of lithium on devel‐
opment. PNAS, Proceedings of the National Academy of Sciences U S A. 06 Aug 
1996;93(16):8455‐8459
[123] Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 16 Mar 
2012 ;148(6):1204‐1222
[124] Nakajima A, Ohizumi Y, Yamada K. Anti‐dementia Activity of Nobiletin, a Citrus 
Flavonoid: A Review of Animal Studies. Clinical Psychopharmacology and Neuroscience. 
Aug 2014;12(2):75‐82
Neuroimmune Dynamics in Alzheimer’s Disease Progression
http://dx.doi.org/10.5772/intechopen.68941
99

